Extended Data Table 1 Summary of COVID-19 severity after COVID-19 vaccination split by serological response

From: SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease

  1. Summary of COVID-19 severity reported in combined follow-up periods after COVID-19 vaccination for all immunocompromised patients in OCTAVE, split by disease subgroup and based on Roche anti-RBD Ig assay result ≥0.8 AU ml−1, low response <380 AU ml−1 and high response >380 AU mL−1 at the post-V2 timepoint.
  2. # % of total OCTAVE infections.
Back to article page